Skip to main content
Log in

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Studies investigating the aripiprazole augmentation treatment of serotonin reuptake inhibitor (SRI)-resistant obsessive-compulsive disorder (OCD) are insufficient. The aim of the present pilot study was to investigate the efficacy and tolerability of flexible doses of aripiprazole as an augmenting agent in SRI-resistant OCD patients.

Methods

OCD patients who met the criteria of this study were followed up with flexible doses of aripiprazole augmentation over a 10-week period. Effectiveness of treatment was evaluated via the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) scales. At the end of the 10-week follow-up period, patients who showed an improvement of ≥30% for the Y-BOCS total score from baseline were considered responders.

Results

Thirty patients met the study inclusion criteria; three patients did not agree to participate, and four patients dropped out of the study. The differences between baseline and scores at 10 weeks for the parameters studied were as follows: Y-BOCS scores: 32.0±6.3–24.0±8.1 (Z=4.2, P<0.05); Y-BOCS compulsion subscore: 15.0±4.2–11.5±4.3 (Z=4.01, P<0.05); Y-BOCS obsession subscore: 17.0±2.6–12.4±4.0 (Z=4.1, P<0.05); and CGI-S scores: 4.8±0.8–3.1±1.2 (Z=3.9, P<0.05). Patients showed a significant improvement over the 10-week study period; however, only seven of 23 patients (30.4%) who completed the study met the criteria determined for treatment response.

Conclusion

Despite the limited number of cases and open-label design of this study, results support the notion that adding aripiprazole to SRIs could be a valid strategy for treatmentresistant OCD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2008;18:364–372.

    Article  PubMed  CAS  Google Scholar 

  2. Decloedt EH, Stein DJ. Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233–242.

    Article  PubMed  CAS  Google Scholar 

  3. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010;12:187–197.

    Google Scholar 

  4. Marazziti D, Pfanner C, Dell’Osso B, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol. 2005;19:392–394.

    Article  PubMed  CAS  Google Scholar 

  5. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010;12:CD008141.

    PubMed  Google Scholar 

  6. Choi YJ. Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009;21:207–213.

    Article  PubMed  Google Scholar 

  7. Soygur H. Pharmacokinetic and pharmacodynamic characteristics of aripiprazole. Klinik Psikofarmakoloji Bulteni. 2008;18:1–6.

    Google Scholar 

  8. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.

    Article  PubMed  CAS  Google Scholar 

  9. Monkul ES, Akdede BB. Aripiprazole: a new atypical antipsyhotic [sic] drug. Klinik Psikofarmakoloji Bulteni. 2005;15:198–203.

    CAS  Google Scholar 

  10. Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol. 2009;24:265–269.

    Article  PubMed  Google Scholar 

  11. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessivecompulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66:49–51.

    Article  PubMed  CAS  Google Scholar 

  12. Sarkar R, Klein J, Kruger S. Aripiprazole augmentation in treatment-refractory obsessivecompulsive disorder. Psychopharmacology (Berl). 2008;197:687–688.

    Article  CAS  Google Scholar 

  13. da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipraminerefractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1550–1551.

    Article  PubMed  Google Scholar 

  14. Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30:688–693.

    Article  PubMed  CAS  Google Scholar 

  15. Tek C, Ulug B, Rezaki BG, et al. Yale-Brown Obsessive Compulsive Scale and US National Institute of Mental Health Global Obsessive Compulsive Scale in Turkish: reliability and validity. Acta Psychiatr Scand. 1995;91:410–413.

    Article  PubMed  CAS  Google Scholar 

  16. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry. 2001;42:161–165.

    Article  PubMed  CAS  Google Scholar 

  17. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.

    Article  PubMed  CAS  Google Scholar 

  18. Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessivecompulsive disorder. Expert Rev Neurother. 2010;10:275–290.

    Article  PubMed  CAS  Google Scholar 

  19. Perani D, Garibotto V, Gorini A, et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008;42:306–314.

    Article  PubMed  Google Scholar 

  20. Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65(suppl. 14):11–17.

    PubMed  CAS  Google Scholar 

  21. Pae CU. Comments on “Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials”. Gen Hosp Psychiatry. 2010;32:448; author reply 449.

    Article  PubMed  Google Scholar 

  22. Arias Horcajadas F, Soto JA, Garcia-Cantalapiedra MJ, Rodriguez Calvin JL, Morales J, Salgado M. Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors. Actas Esp Psiquiatr. 2006;34:147–152.

    PubMed  CAS  Google Scholar 

  23. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65:565–568.

    Article  PubMed  CAS  Google Scholar 

  24. Nelson JC, Thase ME, Trivedi MH, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc snalysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009;11:344–352.

    Article  PubMed  Google Scholar 

  25. Padala PR, Sadiq HJ, Padala KP. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient. J Clin Psychopharmacol. 2006;26:667–668.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mehmet Ak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ak, M., Bulut, S.D., Bozkurt, A. et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. Adv Therapy 28, 341–348 (2011). https://doi.org/10.1007/s12325-011-0011-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0011-7

Keywords

Navigation